Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
Journal
The Lancet. Oncology
Journal Volume
24
Journal Issue
11
Date Issued
2023-11
Author(s)
Rha, Sun Young
Oh, Do-Youn
Yañez, Patricio
Bai, Yuxian
Ryu, Min-Hee
Lee, Jeeyun
Rivera, Fernando
Alves, Gustavo Vasconcelos
Garrido, Marcelo
Shiu, Kai-Keen
Fernández, Manuel González
Li, Jin
Lowery, Maeve A
Çil, Timuçin
Cruz, Felipe Melo
Qin, Shukui
Luo, Suxia
Pan, Hongming
Wainberg, Zev A
Yin, Lina
Bordia, Sonal
Bhagia, Pooja
Wyrwicz, Lucjan S
Abstract
PD-1 inhibitors combined with chemotherapy have shown efficacy in gastric or gastro-esophageal junction cancer. We compared the efficacy and safety of pembrolizumab plus chemotherapy with placebo plus chemotherapy in participants with locally advanced or metastatic HER2-negative gastric or gastro-esophageal junction adenocarcinoma.
Type
journal article